期刊
BJU INTERNATIONAL
卷 100, 期 1, 页码 117-121出版社
WILEY
DOI: 10.1111/j.1464-410X.2007.06915.x
关键词
efficacy; geriatric population; phosphodiesterase inhibitor; safety; sildenafil citrate
Objective To define the efficacy and tolerability of sildenafil in elderly men, as epidemiological data show an increasing life-expectancy of the population, and age is not only correlated with increasing morbidity but also an increase in the prevalence of erectile dysfunction (ED), for which sildenafil, available for > 8 years, is effective and safe across a wide variety of medical comorbidities, severity and causes of ED. Patientsa and methods A database was generated from all sildenafil users in one sexual medicine practice, and data were extracted for men aged > 60 years. The database included data on patient demographics, comorbidities, International Index of Erectile Function (IIEF) scores and adverse events (AEs). The patients were subdivided into those aged 60-69 (group 1), 70-79 (group 2), and >= 80 years (group 3). Analysis of variance was used to assess differences among the three groups for several variables of demographics and erectile response. Results In all, 167 patients were analysed; there were no significant differences in the duration of ED (5 +/- 3 years) or presence of comorbidities among the three groups. With a mean of two risk factors, the overall incidence of comorbidities was hypertension in 37%, dyslipidaemia in 28%, diabetes in 26%, coronary artery disease in 18% and lower urinary tract symptoms in 46%. The efficacy data showed that overall, 54% of men responded to sildenafil, with a mean increase in IIEF EF domain score of 5.7. Within the three groups there was a significant age-related decrease in response rate and IIEF EF domain score with age. However, there was no difference in AE incidence among the three groups, with an overall profile of 18% headache, 8% flushing, 8% dyspepsia, 5% nasal congestion and 2% visual changes. No overt cardiovascular events were reported. Conclusions From these data, sildenafil is an effective agent in elderly men, but had a lower efficacy rate with increasing age, especially in men aged > 80 years. The incidence of side-effects was similar to that in the general population taking sildenafil, with no difference in AEs among the different age groups.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据